Anuh Pharma Limited has informed the Exchange regarding Completion of United States Food and Drug Administration (USFDA) inspection with no Form 483 observations issued.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Anuh Pharma has completed a United States Food and Drug Administration (USFDA) inspection of its facility with no Form 483 observations issued. Form 483 is a document used by the FDA to list conditions observed during inspection that may violate US drug regulations; receiving zero observations means the inspectors found no significant compliance issues. This is a positive outcome for the company as it supports continued eligibility to manufacture and supply products to the highly regulated US pharmaceutical market. A clean inspection typically strengthens buyer confidence and reduces the risk of regulatory action, import alerts, or supply disruptions.
Positive for shareholders — a clean USFDA inspection reinforces Anuh Pharma's compliance standing, supports its US export business, and reduces near-term regulatory risk for its manufacturing operations.